Peregrine Pharmaceuticals to Present at BIO CEO & Investor Conference 2007

Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China

Peregrine Pharmaceuticals Establishes Wholly Owned Subsidiary in China

Peregrine Pharmaceuticals Files Shelf Registration Statement on Form S-3

Study Shows Potential of Targeted Microbubbles Using Peregrine's VTA Technology to Identify Which Cancer Patients Would Benefit From Anti-Angiogenesis Therapy

Avid Bioservices and Halozyme Therapeutics Extend Commercial Manufacturing Agreement

Peregrine Pharmaceuticals and Biotecnol to Collaborate on Development of Immunocytokine Fusion Proteins for Cancer and Anti-Viral Indications

Peregrine Pharmaceuticals Reports Preclinical Data That Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Human Prostate Tumors by 94 Percent

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter Fiscal Year 2007

Peregrine Pharmaceuticals to Announce Second Quarter FY 2007 Financial Results